1297 related articles for article (PubMed ID: 33113776)
1. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
2. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY; McKeage K; Scott LJ
Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
[TBL] [Abstract][Full Text] [Related]
3. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors.
Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E
Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655
[TBL] [Abstract][Full Text] [Related]
4. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS
Front Immunol; 2019; 10():1921. PubMed ID: 31497013
[TBL] [Abstract][Full Text] [Related]
5. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
6. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
7. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the preclinical analgesic efficacy of naturally derived, orally administered oil forms of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and their 1:1 combination.
Linher-Melville K; Zhu YF; Sidhu J; Parzei N; Shahid A; Seesankar G; Ma D; Wang Z; Zacal N; Sharma M; Parihar V; Zacharias R; Singh G
PLoS One; 2020; 15(6):e0234176. PubMed ID: 32497151
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
10. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M
Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922
[TBL] [Abstract][Full Text] [Related]
11. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
[TBL] [Abstract][Full Text] [Related]
12. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
13. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials.
Marková J
Neurodegener Dis Manag; 2019 Apr; 9(2s):9-13. PubMed ID: 30657024
[TBL] [Abstract][Full Text] [Related]
14. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.
Ross HR; Napier I; Connor M
J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906
[TBL] [Abstract][Full Text] [Related]
16. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
[TBL] [Abstract][Full Text] [Related]
17. Botanically-Derived Δ
Fitzpatrick JM; Hackett B; Costelloe L; Hind W; Downer EJ
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335126
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
19. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]